Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  The Journal of Dermatologic Surgery and Oncology

• Publication date

  1993-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/J.1524-4725.1993.TB00989.XPMID 8245304
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guérin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients

  2004cited by this paper
• Therapy for cutaneous melanoma: an update.

  1990cited by this paper
• BCG immunotherapy in stage I melanoma patients

  1986cited by this paper
• A randomized trial of adjuvant chemotherapy and immunotherapy in stage I and stage II cutaneous melanoma. An interim report

  1985cited by this paper
• Adjuvant combination immunotherapy (BCG and levamisole) in malignant melanoma.

  1985cited by this paper
• Controlled Study with Imidazole Carboxamide (DTIC), DTIC + Bacillus Calmette-Guérin (BCG), and DTIC + Corynebacterium Parvum in Advanced Malignant Melanoma

  1984cited by this paper
• ADJUVANT BCG IMMUNOTHERAPY FOR MALIGNANT MELANOMA?

  1984cited by this paper
• A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.

  1982cited by this paper
• Combination chemotherapy plus BCG in the treatment of disseminated malignant melanoma: a Southwest Oncology Group Study.

  1982cited by this paper
• Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities.

  1982cited by this paper
• Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.

  1981cited by this paper
• Treatment of disseminated malignant melanoma with high‐dose oral BCG

  1981cited by this paper
• Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma

  1979cited by this paper
• Adjuvant immunotherapy of malignant melanoma

  1979cited by this paper
• Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.

  1978cited by this paper
• Randomized trial of adjuvant therapy for “high risk” primary malignant melanoma

  1978cited by this paper
• Intralesional BCG application in malignant melanoma.

  1976cited by this paper
• Intralesional BCG in the treatment of metastatic malignant melanoma

  1976cited by this paper
• The use of oral BCG in the treatment or metastatic malignant melanoma.

  1976cited by this paper
• Use of oral and intraperitoneal BCG in the treatment of malignant melanoma and adenocarcinoma.

  1975cited by this paper
• Oral bacille Calmette Guérin immunostimulation in malignant melanoma.

  1975cited by this paper
• Immunologic approaches to various types of cancer with the use of BCG and purified protein derivatives.

  1973cited by this paper
• Mumps virus and BCG vaccine in metastatic melanoma.

  1973cited by this paper
• Immunotherapy in Patients with Melanoma

  1973cited by this paper
• Immunotherapy of melanoma with intralesional BCG.

  1973cited by this paper
• Treatment of malignant melanoma by intratumoral injection of BCG.

  1973cited by this paper
• Complications of BCG immunotherapy in patients with cancer.

  1973cited by this paper
• Immunotherapy of patients with cancer.

  1973cited by this paper
• Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG.

  1972cited by this paper
• Immunological factors which influence response to immunotherapy in malignant melanoma.

  1970cited by this paper
• CASE OF INTESTINAL OBSTRUCTION BY MECKEL'S DIVERTICULUM.

  1919cited by this paper

• Regional Therapies for Melanoma and Merkel Cell Carcinoma.

  2025cites this paper
• Anatomic Location Predicts Response Rates: Real World Outcomes with Over 1,100 Cycles of Talimogene Laherparepvec (TVEC) Description: A Retrospective Review of a Prospectively Maintained Database.

  2025cites this paper
• Advances in Bacterial Lysate Immunotherapy for Infectious Diseases and Cancer

  2024cites this paper
• Thermosensitive hydrogel delivery of BCG lysates and tumor antigens: A novel strategy for melanoma immunoprevention and therapeutics.

  2024cites this paper
• Efficacy of Bacillus Calmette-Guérin in Cancer Prevention and Its Putative Mechanisms

  2024cites this paper
• Therapeutic Treatment Options for In-Transit Metastases from Melanoma

  2024cites this paper
• Intralesional and Infusional Updates for Metastatic Melanoma

  2024cites this paper
• Current and Emerging Intralesional Immunotherapies in Cutaneous Oncology.

  2024cites this paper
• Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG

  2023cites this paper
• Bacillus Calmette-Guerin (BCG) induces superior anti-tumour responses by Vδ2+ T cells compared with the aminobisphosphonate drug zoledronic acid

  2022cites this paper
• BCG hydrogel promotes CTSS-mediated antigen processing and presentation, thereby suppressing metastasis and prolonging survival in melanoma

  2022cites this paper
• Management of In-Transit Metastases

  2022cites this paper
• In-transit metastatic cutaneous melanoma: current management and future directions

  2021cites this paper
• Repurposing Infectious Diseases Vaccines Against Cancer

  2021cites this paper
• BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases.

  2021cites this paper
• Local and regional therapy for primary and locally recurrent melanoma.

  2021cites this paper
• Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma

  2020cites this paper
• Clinical and molecular insights into BCG immunotherapy for melanoma

  2020cites this paper
• Injectable Therapies for Regional Melanoma.

  2020cites this paper
• Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years.

  2019cites this paper
• Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.

  2018cites this paper
• Intralesional PV‐10 for the treatment of in‐transit melanoma metastases—Results of a prospective, non‐randomized, single center study

  2018cites this paper
• Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience

  2018cites this paper
• Management of in‐transit melanoma metastases: a review

  2018cites this paper
• Do you know your guidelines? Diagnosis and management of cutaneous head and neck melanoma

  2018cites this paper
• Treatment of Metastatic Melanoma

  2018cites this paper
• Millennium mini-review

  2017cites this paper
• The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy

  2017cites this paper
• Results of a phase II, open‐label, non‐comparative study of intralesional PV‐10 followed by radiotherapy for the treatment of in‐transit or metastatic melanoma

  2017cites this paper
• Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.

  2016cites this paper
• Trained immunity: consequences for the heterologous effects of BCG vaccination.

  2015cites this paper
• Bacillus Calmette-Guerin injections for melanoma immunotherapy: potential for a false-positive PET/CT.

  2015cites this paper
• Harnessing the Host Immune Response to Infection – BCG Immunotherapy for Bladder Cancer

  2015cites this paper
• A Computational Simulation of the Interaction Between Immune and Neuroendocrine Systems

  2015cites this paper
• Cancer vaccines

  2015cites this paper
• The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options

  2015cites this paper
• Surgical management of metastatic melanoma in the era of targeted systemic therapies

  2015cites this paper
• Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma

  2014cites this paper
• Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review

  2014cites this paper
• Author's response to reviews Title:The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies Authors:

  2014cites this paper
• The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies

  2014cites this paper
• Surgical treatment options for stage IV melanoma.

  2014cites this paper
• Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma

  2014cites this paper
• Treatment of Primary Tumor and Locoregional Disease

  2013cites this paper
• Malignes Melanom S3‐Leitlinie “Diagnostik, Therapie und Nachsorge des Melanoms”

  2013cites this paper
• Melanoma vaccines: trials and tribulations

  2013cites this paper
• Malignant Melanoma S3‐Guideline “Diagnosis, Therapy and Follow‐up of Melanoma”

  2013cites this paper
• Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III disease.

  2013cites this paper
• Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: Management of stage IV disease.

  2013cites this paper
• NCCN Melanoma Clinical Practice Guidelines in Oncology

  2012cites this paper
• MelanomaPractice Guidelines in Oncology

  2012cites this paper
• Re-inventing intratumoral immunotherapy for melanoma.

  2011cites this paper
• 20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters

  2011cites this paper
• Cutaneous Metastases from Malignant Melanoma: Clinical Features and New Therapeutic Perspectives

  2011cites this paper
• Long‐term outcome of isolated limb perfusion with tumour necrosis factor‐α for patients with melanoma in‐transit metastases

  2011cites this paper
• Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha

  2011cites this paper
• Infection, immunoregulation, and cancer

  2011cites this paper
• New therapeutic options in the medical management of advanced melanoma.

  2010cites this paper
• Velimogene aliplasmid

  2010cites this paper
• Melanoma cutáneo

  2010cites this paper
• [Cutaneous melanoma].

  2010cites this paper
• Immunotherapy for malignant melanoma--tracing Ariadne's thread through the labyrinth.

  2009cites this paper
• Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma

  2009cites this paper
• In-transit metastasis from melanoma presenting as lymphangiectasis: a case report.

  2009cites this paper
• Chemoablation of metastatic melanoma using intralesional Rose Bengal

  2008cites this paper
• A rational surgical approach to the treatment of distant melanoma metastases.

  2008cites this paper
• Therapy for unresectable recurrent and in-transit extremity melanoma.

  2008cites this paper
• The use of mycobacterial adjuvant-based agents for immunotherapy of cancer.

  2008cites this paper
• Melanoma vaccines

  2008cites this paper
• Treatment of wild‐type gastrointestinal stromal tumor (WT‐GIST) with imatinib and sunitinib

  2008cites this paper
• Pathogen-associated molecular pattern in cancer immunotherapy.

  2008cites this paper
• The European approach to in-transit melanoma lesions

  2008cites this paper
• Conjunctival melanoma in a six‐year‐old female

  2008cites this paper
• Phase I/II study of topical imiquimod and intralesional interleukin‐2 in the treatment of accessible metastases in malignant melanoma

  2007cites this paper
• A systematic review of the safety of topical therapies for atopic dermatitis

  2007cites this paper
• Topical immunomodulators in dermatology Topical immunomodulators in dermatology Topical immunomodulators in dermatology Topical immunomodulators in dermatology Topical immunomodulators in dermatology

  2004cites this paper
• Topical immunomodulators in dermatology.

  2004cites this paper
• The role of isolated limb perfusion for melanoma confined to the extremities.

  2003cites this paper
• Inverse association between melanoma and previous vaccinations against tuberculosis and smallpox: results of the FEBIM study.

  2002cites this paper
• Campbell De Morgan's 'Observations on cancer', and their relevance today.

  2002cites this paper
• Significance of tumor-associated antigens in the diagnosis and therapy of cancer: an overview.

  2002cites this paper
• Vaccination and melanoma risk

  2002cites this paper
• Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV)

  2002cites this paper
• Diagnostik und adjuvante Therapie des malignen Melanoms

  2002cites this paper
• Immunology and immunotherapy of human cancer: present concepts and clinical developments.

  2000cites this paper
• Tumour immunotherapy: the adjuvant treatment of the 21st century?

  2000cites this paper
• Cancer vaccines

  2000cites this paper
• Sentinel node biopsy: who needs it?

  2000cites this paper
• Correspondence

  1999cites this paper
• Adjuvant treatment of melanoma using placebo or no therapies as control-arm: is it ethically correct?

  1999cites this paper
• Purified protein derivative treatment for skin lesions of adult T-cell leukaemia/lymphoma.

  1999cites this paper
• Adjuvant therapy for melanoma: How should we respond to high-dose interferon?

  1998cites this paper
• Topical Immunotherapy of Malignant Melanoma

  1997cites this paper
• Adjuvant therapy for cutaneous malignant melanoma.

  1997cites this paper
• Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state.

  1997cites this paper
• Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-γ, which inhibits B16F10 melanoma cell growth in vitro

  1996cites this paper
• Primary inoculation tuberculosis after immunotherapy for malignant melanoma with BCG vaccine.

  1996cites this paper
• Bacillus Calmette-Guérin plus interleukin-2 and/or granulocyte/macrophage-colony-stimulating factor enhances immunocompetent cell production of interferon-gamma, which inhibits B16F10 melanoma cell growth in vitro.

  1996cites this paper
• The role of adjuvant therapy in melanoma management

  1995cites this paper
• [Future of malignant stage I melanoma. Immunology and immunotherapy].

  1995cites this paper